| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
m-3M3FBS targets phospholipase C (PLC), activating all PLC isotypes including PLCβ2. By directly activating PLC, it stimulates the increase in cytoplasmic calcium, inositol phosphate formation, and superoxide generation. The compound also up-regulates Bax levels and down-regulates Bcl-2 levels, inducing apoptosis in certain cell types.
|
|---|---|
| ln Vitro |
In U937 cells, m-3M3FBS (5–50 μM) increases the phosphoinositide formation [1]. Primary monocytes are unaffected by m-3M3FBS (50 μM; 24 hours), whereas leukemia cell lines U937 and THP-1 are [3]. In U937 cells, m-3M3FBS (50 μM; 24 hours) causes apoptosis [3].
In vitro, m-3M3FBS activates PLC in a variety of cell types, stimulating intracellular Ca²⁺ release, inositol phosphate production, and superoxide generation. It triggers mitochondrial damage and activates NLRP10 inflammasome in keratinocytes. The compound induces apoptosis in monocytic leukemia cell lines such as U937 and THP-1 and inhibits their growth. |
| ln Vivo |
In vivo activity data for m-3M3FBS is limited in publicly available sources. The compound is primarily used as a research tool in cell-based assays to study PLC signaling and calcium homeostasis. It has been used to study PLC signaling in cells and animals, often in conjunction with the PLC inhibitor U-73122.
|
| Enzyme Assay |
Non-cellular enzyme assays for m-3M3FBS involve measuring PLC activity in vitro. PLC enzyme is incubated with its substrate phosphatidylinositol 4,5-bisphosphate (PIP₂) and varying concentrations of m-3M3FBS. Production of inositol phosphates is measured using radiolabeled substrates or by ELISA. Activation of PLC is confirmed by increased product formation.
|
| Cell Assay |
Cell viability assay [3]
Cell Types: U937 and THP-1 Cell Tested Concentrations: 50 μM Incubation Duration: 24 hrs (hours) Experimental Results: Inhibited the growth of leukemia cell lines U937 and THP-1, but not primary monocytes. Cell viability assay [3] Cell Types: U937 Cell Tested Concentrations: 50 μM Incubation Duration: 24 hrs (hours) Experimental Results: The apoptosis rate of cells treated with m-3M3FBS was 53.9%. In vitro cellular experiments involve treating cells with m-3M3FBS and measuring downstream signaling events. Intracellular calcium levels are measured using fluorescent indicators such as Fura-2 or Fluo-4. Inositol phosphate production is measured using radiolabeled myo-inositol. Superoxide generation is measured using chemiluminescent or colorimetric assays. Apoptosis is assessed by measuring Bax and Bcl-2 levels and by standard apoptosis assays. |
| Animal Protocol |
In vivo animal studies for m-3M3FBS are limited. The compound has been used to study PLC signaling in animals, often in conjunction with the PLC inhibitor U-73122. Specific protocols and dosing regimens are not detailed in publicly available sources.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for m-3M3FBS is limited. The compound has a molecular weight of 343.36 g/mol (C₁₆H₁₆F₃NO₂S). It is soluble in DMSO (>10 mM). As a research tool, its PK properties have not been extensively characterized.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for m-3M3FBS is limited. The compound induces apoptosis in certain cell types and should be handled with appropriate safety precautions. No LD₅₀ or specific toxicity information has been reported.
|
| References |
|
| Additional Infomation |
2,4,6-Trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide is a sulfonamide.
m-3M3FBS is a cell-permeable, specific activator of phospholipase C (PLC). It stimulates PLC-mediated intracellular Ca²⁺ release, inositol phosphate production, and superoxide generation. The compound induces apoptosis in monocytic leukemia cells and is used as a research tool to study PLC signaling pathways. This product is for research purposes only and is not for human therapeutic use. |
| Molecular Formula |
C16H16F3NO2S
|
|---|---|
| Molecular Weight |
343.36
|
| Exact Mass |
343.085
|
| CAS # |
200933-14-8
|
| PubChem CID |
761523
|
| Appearance |
White to off-white solid powder
|
| Density |
1.316g/cm3
|
| Boiling Point |
420ºC at 760mmHg
|
| Melting Point |
114-114.8ºC(lit.)
|
| Flash Point |
207.8ºC
|
| Vapour Pressure |
2.92E-07mmHg at 25°C
|
| Index of Refraction |
1.547
|
| LogP |
5.585
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
23
|
| Complexity |
488
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC(=C(C(=C1)C)S(=O)(=O)NC2=CC=CC(=C2)C(F)(F)F)C
|
| InChi Key |
ZIIUUSVHCHPIQD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H16F3NO2S/c1-10-7-11(2)15(12(3)8-10)23(21,22)20-14-6-4-5-13(9-14)16(17,18)19/h4-9,20H,1-3H3
|
| Chemical Name |
2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide
|
| Synonyms |
m3M3FBS m 3M3FBS m-3M3FBS
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~291.24 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (7.28 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9124 mL | 14.5620 mL | 29.1240 mL | |
| 5 mM | 0.5825 mL | 2.9124 mL | 5.8248 mL | |
| 10 mM | 0.2912 mL | 1.4562 mL | 2.9124 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
